Scott & White Healthcare researching treatments for rare cancers

Scott & White’s Cancer Research Institute (CRI) has launched two clinical trials targeting cancers that affect both adults and children.

“These studies may lead to eventual development of agents that we hope will improve quality and duration of life,” said Arthur Frankel, M.D., director of the CRI, and director of Scott & White’s Cancer Center and division of hematology/oncology.

One of the studies aims to find the maximum safest dose of an agent for treatment of T-cell lymphomas and leukemia, including several skin lymphomas. These cutaneous or skin lymphomas represent a variety of cancers with various symptoms and outcomes, including micosis fungoides, a slow-growing lymphoma that primarily affects the skin, and Sezary syndrome, a more aggressive cutaneous lymphoma.

1,500 new cases of this form of lymphoma are reported each year in the U.S., compared to 58,870 new cases for all types of non-Hodgkin lymphoma. Men are twice as likely as women to have the disease, which typically appears in adults 55 years and older.

“We want to determine if this agent is effective in destroying cancer cells using varying doses,” said Dr. Frankel, who is also principal investigator in both studies. Eligible subjects are those 18 years or older who have failed one round of conventional treatment.

A second clinical trial at the Scott & White Cancer Research Institute seeks to determine the efficacy of drugs aimed at B-cell leukemia and lymphoma, including childhood leukemia, using an immunotoxin that targets cancer cells and kills them. The agent treats chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow. Approximately 15,000 people, primarily over age 50, are diagnosed with CLL each year in the U.S.

The agent involved in the clinical trial also targets acute lymphocyctic leukemia (ALL) or childhood leukemia, a cancer of the blood and bone marrow that is the most common type of cancer in children under 15, occurring in about one of every 29,000 children in the U.S.

“In this phase I trial, we want to determine the side effects and best dose of the agent in treating patients with B-cell leukemia or lymphoma who have relapsed or not responded to treatment,” said Frankel.

###

For additional information about the clinical trials and patient eligibility, contact Dusten Cardinal at pager (254) 724-0040.

The Scott & White Cancer Research Institute is a leader in Phase I clinical trials using targeted protein therapy to treat hematologic malignancies. Many of the agents developed at the CRI are made up of toxic proteins that selectively kill tumor cells.

source : www.eurekalert.org

Related News:

• Research May Provide Potential Target For New Therapies To Limit Metastasis Of Primary Breast Cancers
• Predictive Biosciences To Present Novel Combination Approach To Molecular Cancer Diagnostics At 2010 Genitourinary Cancers Symposium
• Pretreatment SUV Associated With Head And Neck Cancer Treatment Outcomes, May Help Decide Treatment Plans
• Proton Beam Therapy Shows Encouraging Long-term Outcome For Patients With Locally Advanced Sinonasal Cancers
• The ASCO Cancer Foundation Awards $25,000 To Young Researchers For Important Contributions To Genitourinary Cancers Research
• Cancers can re-seed themselves after chemo, surgery or radiation
• UT Southwestern Program Tackles Difficult Head, Neck Cancers
• Map Of Fear Memory Formation Extended By Brain Scientists
• Lowered Educational Attainment Found In Childhood Survivors Of CNS Cancers And Leukemia
• Caffeine Abstinence: An Ineffective And Potentially Distressing Tinnitus Therapy